These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23065516)

  • 1. Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells.
    Hiwase DK; Saunders VA; Nievergall E; Ross DD; White DL; Hughes TP
    Haematologica; 2013 Jun; 98(6):896-900. PubMed ID: 23065516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
    Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
    Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
    Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
    Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.
    Davies A; Jordanides NE; Giannoudis A; Lucas CM; Hatziieremia S; Harris RJ; Jørgensen HG; Holyoake TL; Pirmohamed M; Clark RE; Mountford JC
    Leukemia; 2009 Nov; 23(11):1999-2006. PubMed ID: 19710702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
    Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nilotinib enhances the efficacy of conventional chemotherapeutic drugs in CD34⁺CD38⁻ stem cells and ABC transporter overexpressing leukemia cells.
    Wang F; Wang XK; Shi CJ; Zhang H; Hu YP; Chen YF; Fu LW
    Molecules; 2014 Mar; 19(3):3356-75. PubMed ID: 24651611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
    Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL
    Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
    Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
    Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
    Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.
    Hiwase DK; White DL; Powell JA; Saunders VA; Zrim SA; Frede AK; Guthridge MA; Lopez AF; D'Andrea RJ; To LB; Melo JV; Kumar S; Hughes TP
    Leukemia; 2010 Apr; 24(4):771-8. PubMed ID: 20130598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.
    Copland M; Hamilton A; Elrick LJ; Baird JW; Allan EK; Jordanides N; Barow M; Mountford JC; Holyoake TL
    Blood; 2006 Jun; 107(11):4532-9. PubMed ID: 16469872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
    Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Müller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL
    Blood; 2012 Feb; 119(6):1501-10. PubMed ID: 22184410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.
    Giannoudis A; Davies A; Lucas CM; Harris RJ; Pirmohamed M; Clark RE
    Blood; 2008 Oct; 112(8):3348-54. PubMed ID: 18669873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
    Mahon FX; Hayette S; Lagarde V; Belloc F; Turcq B; Nicolini F; Belanger C; Manley PW; Leroy C; Etienne G; Roche S; Pasquet JM
    Cancer Res; 2008 Dec; 68(23):9809-16. PubMed ID: 19047160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
    Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
    Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
    Corbin AS; O'Hare T; Gu Z; Kraft IL; Eiring AM; Khorashad JS; Pomicter AD; Zhang TY; Eide CA; Manley PW; Cortes JE; Druker BJ; Deininger MW
    Cancer Res; 2013 Sep; 73(18):5775-86. PubMed ID: 23887971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib.
    Hatziieremia S; Jordanides NE; Holyoake TL; Mountford JC; Jørgensen HG
    Exp Hematol; 2009 Jun; 37(6):692-700. PubMed ID: 19394750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy.
    Hiwase DK; White D; Zrim S; Saunders V; Melo JV; Hughes TP
    Leukemia; 2010 Mar; 24(3):658-60. PubMed ID: 20010623
    [No Abstract]   [Full Text] [Related]  

  • 19. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
    Corbin AS; Agarwal A; Loriaux M; Cortes J; Deininger MW; Druker BJ
    J Clin Invest; 2011 Jan; 121(1):396-409. PubMed ID: 21157039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.
    Eadie LN; Saunders VA; Hughes TP; White DL
    Leuk Lymphoma; 2013 Mar; 54(3):569-78. PubMed ID: 22845311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.